000 | 01938 a2200577 4500 | ||
---|---|---|---|
005 | 20250514034023.0 | ||
264 | 0 | _c20021205 | |
008 | 200212s 0 0 eng d | ||
022 | _a0021-9150 | ||
024 | 7 |
_a10.1016/s0021-9150(01)00770-5 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWoodman, Richard J | |
245 | 0 | 0 |
_aLeukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension. _h[electronic resource] |
260 |
_bAtherosclerosis _cJul 2002 |
||
300 |
_a175-81 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAnalysis of Variance |
650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
650 | 0 | 4 | _aBlood Flow Velocity |
650 | 0 | 4 |
_aC-Reactive Protein _xanalysis |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
650 | 0 | 4 |
_aDiabetic Angiopathies _xcomplications |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypertension _xcomplications |
650 | 0 | 4 |
_aInflammation Mediators _xanalysis |
650 | 0 | 4 |
_aInterleukin-6 _xanalysis |
650 | 0 | 4 | _aLeukocyte Count |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMultivariate Analysis |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aReference Values |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aSampling Studies |
650 | 0 | 4 |
_aSelectins _xanalysis |
650 | 0 | 4 | _aSensitivity and Specificity |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xanalysis |
700 | 1 | _aWatts, Gerald F | |
700 | 1 | _aPuddey, Ian B | |
700 | 1 | _aBurke, Valerie | |
700 | 1 | _aMori, Trevor A | |
700 | 1 | _aHodgson, Jonathan M | |
700 | 1 | _aBeilin, Lawrence J | |
773 | 0 |
_tAtherosclerosis _gvol. 163 _gno. 1 _gp. 175-81 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0021-9150(01)00770-5 _zAvailable from publisher's website |
999 |
_c11944511 _d11944511 |